The global image of European cannabis is changing, again.
Back in 2016, there were very few North Americans interested in what was happening this side of the Atlantic. A couple of early movers, including Tilray’s Brendan Kennedy, were in London raising money and engaging policymakers. Researchers, advocacy groups, and activists made up 95% of the legal European ‘cannabis sector’.
When Germany legalised medical cannabis in 2017 something changed. European cannabis, and the commercial opportunities that would come with it, were now a very real possibility. Licences became highly sought after and executives from Canadian companies began flying in for meetings with politicians, regulators, and in some cases army colonels.